Radiation and immunotherapy combo tested in advanced lung cancer
NCT ID NCT03307759
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-phase trial tested the safety of giving a type of precise radiation (SABR) either before or after the immunotherapy drug pembrolizumab in 13 people with advanced non-small cell lung cancer. The study aimed to see how well patients tolerated the combination and whether it helped shrink tumors. The trial was terminated early, so the full results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (a drug that helps the immune system fight cancer) and stereotactic ablative body radiotherapy (a precise type of radiation)
What this could lead to
If successful, this could point toward a more effective way to combine radiation and immunotherapy for advanced lung cancer.
What could go wrong
This was a very early, small Phase 1 trial that was terminated early, so results are limited. The combination may cause serious side effects and may not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.